US OptionsDetailed Quotes

TARS241220P50000

Watchlist

5.50
0.000.00%

15min DelayClose Dec 10 15:59 ET

0.00High0.00Low

Tarsus Pharmaceuticals Stock Discussion

Jerry Kronenberg

Nov 13 15:29

Columns Tarsus Pharmaceuticals Gains Some 15% After Hours on Better-Than-Expected Q3 Results

$Tarsus Pharmaceuticals (TARS.US)$ rose some 15% in after-hours trading Wednesday after the biotech reported a narrower-than-Q3 expected loss and better-than-forecast quarterly revenues.
TARS – which makes XDEMVY, a prescription eye drop to treat optical disease Demodex blepharitis – gained 14.5% to $53.25 shortly before 4:30 p.m. ET after unveiling a $0.61 Q3 loss, beating the $0.92 that analysts had reportedly f...

MMu

Oct 29 15:16

$Tarsus Pharmaceuticals (TARS.US)$ wonder which 2 pharmas are bidding for Tarsus!!

Stock_Drift

Oct 28 04:33

Pre Market Ticks. 5:32am 10/28

$Jet.AI (JTAI.US)$ $ProShares UltraShort Bloomberg Crude Oil ETF (SCO.US)$ $Phunware (PHUN.US)$ $ImmunityBio (IBRX.US)$ $Longeveron (LGVN.US)$ $BIOSIG TECHNOLOGIES INC (BSGM.US)$ $Tarsus Pharmaceuticals (TARS.US)$ $XTL Biopharmaceuticals (XTLB.US)$ $LENZ Therapeutics (LENZ.US)$ $TC BioPharm (TCBP.US)$ $Top Wealth Group Holding (TWG.US)$ $Healthcare Triangle (HCTI.US)$ $Pixie Dust Technologies(Delisted) (PXDT.US)$
📊⚡️📊

Jaguar8

Aug 8 15:17

NEWS

$Tarsus Pharmaceuticals (TARS.US)$
Tarsus Reports Second Quarter and Year-to-Date 2024 Financial Results and Recent Business Achievements
Tarsus Pharmaceuticals (NASDAQ: TARS) reported strong Q2 2024 financial results, with XDEMVY® net product sales reaching $40.8 million, a 65% increase from Q1.
Year-to-date sales totaled $65.5 million.
The company delivered over 37,000 bottles to patients in Q2 and achieved an impressive gross-to-net discount of 44%.
Tarsus expanded payer coverage, incl...

Moomoo AI

Mar 1 12:53

Analysts predict Tarsus Pharmaceuticals' growth to outpace the industry with a 5x annualised growth by 2024. The upgraded price target indicates an expected increase in the business's intrinsic value.

Analysts Are Upgrading Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) After Its Latest Results

Kevin Travers

Feb 27 10:02

Columns Biotechnology Stocks Climbing on Earnings and Test Results: What to Watch

$Viking Therapeutics (VKTX.US)$skyrocketed 77% after positive drug trial news Tuesday, leading to what proved to be a strong morning for pharmaceutical stocks.
Here are some top stocks in the sector climbing on drug trial and earnings news:
$Janux Therapeutics (JANX.US)$shares shot up 205% to $36.00 after the company announced updated clinical data for both of its clinical programs, reaching over $1.50B in market cap.
$Ligand Pharmaceuticals (LGND.US)$gained 23%...

Meltyy

Jan 24 03:25

Ph2 readouts in Q1 2024...

$Pfizer (PFE.US)$ Phase 2
$Leap Therapeutics (LPTX.US)$ Phase 2
$Vera Therapeutics (VERA.US)$ Phase 2b
$4D Molecular Therapeutics (FDMT.US)$ Phase 2
$Adverum Biotechnologies (ADVM.US)$ Phase 2
$Denali Therapeutics (DNLI.US)$ Phase 2
$Akero Therapeutics (AKRO.US)$ Phase 2b
$Spruce Biosciences (SPRB.US)$ Phase 2
$Xencor (XNCR.US)$ Phase 2
$Alnylam Pharmaceuticals (ALNY.US)$ Phase 2
$Harmony Biosciences (HRMY.US)$ Phase 2
$Annexon (ANNX.US)$ Phase 2a
$Roivant Sciences (ROIV.US)$...

Moomoo AI

Jan 12 06:52

Insider transactions at Tarsus Pharmaceuticals over the past year are not encouraging. Despite insiders owning shares, the net investment doesn't inspire much confidence.

Tarsus Pharmaceuticals Insiders Benefitted From Selling Stock At US$12.72

Bigmoney Dreamer

Dec 8, 2023 02:35

$Tarsus Pharmaceuticals (TARS.US)$ 👀

MangoXoXo

Aug 3, 2023 00:30

$Tarsus Pharmaceuticals (TARS.US)$ 👀👀

No comment yet